Date Time
Dana-Farber research leads to better understanding of immune system in kidney cancer
Two research papers highlight single-cell dissection of kidney tumors to identify new immunotherapy treatments and targets
In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn’t work for all patients, and almost all patients, no matter how they respond initially, become more resistant to treatment over time. The immune system plays a critical role in kidney cancer disease progression and in response to therapies, and so a fundamental challenge in the field is to understand the underlying “immune circuitry” of this disease.
Dana-Farber research leads to better understanding of the immune system in kidney cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Date Time
Personalized vaccine produces long-lasting anti-tumor response in patients with melanoma, study shows
Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study.
The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the vaccine, known as NeoVax, which works by targeting specific proteins on each patient’s tumor cells. The researchers found that, nearly four years after vaccination, the patients’ immune system cells were active not only against tumor cells with those distinctive proteins, but also spread to other proteins found in those patients’ tumor cells.
E-Mail
BOSTON - Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women s Hospital, and the Broad Institute of MIT and Harvard report in a new study.
The findings, published online today by the journal
Nature Medicine, demonstrate the staying power of the immune response generated by the vaccine, known as NeoVax, which works by targeting specific proteins on each patient s tumor cells. The researchers found that, nearly four years after vaccination, the patients immune system cells were active not only against tumor cells with those distinctive proteins, but also spread to other proteins found in those patients tumor cells.